PPIDT00439
Drug Information
| Name | Spesolimab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15626 |
| Type | biotech |
| Indication | Spesolimab is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.[L50391] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
150 mg/1mL
|
| Injection | Intravenous |
60 mg/1mL
|
| Injection, solution | Subcutaneous |
150 mg
|
| Injection, solution, concentrate | Intravenous |
450 mg
|
| Solution | Intravenous |
60 mg / mL
|
| Solution | Subcutaneous |
150 mg / mL
|
| Injection, solution, concentrate | Intravenous |
450 mg/7.5ml
|